Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 18 Oct 2025 |
| Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025 | 14 Oct 2025 |
| Genmab A/S has published its Articles of Association | 30 Sept 2025 |
| Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model | 29 Sept 2025 |
| Grant of Restricted Stock Units and Warrants to Employees in Genmab | 26 Sept 2025 |
| Major Shareholder Announcement | 23 Sept 2025 |